Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company

For Immediate Release

Chicago, IL –August 14, 2017 - Stocks in this week’s article include The Chemours Company(NYSE:CC Free Report), Haemonetics Corporation (NYSE:HAE Free Report) and The Brink's Company (NYSE:BCO Free Report).

3 Best Stocks with Upgraded Broker Ratings to Invest in Now

You must be thinking that investing in stocks is one of the easiest things to do. But it’s not as easy as it may seem.

For this, one has to understand the fundamentals of a company and place them against the present economic background to figure out how it may fare as an investment. One way to cut this task out is to follow broker recommendation.

Brokers have more insight into what’s happening in a particular company as they directly communicate with management. Further, they have a deeper understanding of the overall industry.

Specifically, brokers research on a company’s publicly available financial statements, listen to conference calls and engage in talks directly with top management. At times, they even talk with customers to gauge what they like or dislike about the products and services offered by the company.

So, after thorough research, brokers decide to rate that particular company’s stock. Naturally, when an analyst upgrades a stock, you can easily rely on it.

However, solely depending on analysts’ upgrades is not the right way to build your investment portfolio. You should also take into consideration other factors to ensure solid returns.

Picking the Winning Strategy

We have a screening strategy that will help in your search for potential winners:

Broker Rating Upgrades (4 weeks) of 1% ore more: The screen selects stocks that have witnessed broker rating upgrades of 1% more over the last four weeks.

Current Price greater than 5: The stocks must be trading above $5.

Average 20-day Volume greater than 100,000: A large trading volume guarantees that the stock is easily tradable.

Zacks Rank equal to #1 or #2: No matter whether market conditions are good or bad, stocks with a Zacks Rank #1 (Strong Buy) or #2 (Buy) have a proven record of success. You can see the complete list of today’s Zacks #1 Rank stocks here.

VGM Score equal to A or B: Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank #1 or 2 offer the best upside potential.

Here are three of the four stocks that made it through the screen:

Headquartered in Wilmington, DE, The Chemours Company (NYSE:CCFree Report) provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company’s earnings are expected to grow at the rate of 255.4% in the current year. The stock has witnessed 16.7% upward revision in broker ratings over the past four weeks.

Haemonetics Corporation (NYSE:HAEFree Report), headquartered in Braintree, MA, is a healthcare company, providing hematology products and solutions. The company’s current year earnings are expected to grow at the rate of 4.8%. The stock has witnessed 11.1% upward revision in broker ratings over the past four weeks.

Richmond, VA-based The Brink's Company (NYSE:BCOFree Report) offers secure transportation, cash management services, and other security-related services worldwide. The company’s earnings are expected to grow at the rate of 35.5% for the current fiscal year. The stock has witnessed 25% upward revision in broker ratings over the past four weeks.

Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back testing software.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use. Each week, Zacks Profit from the Pros free email newsletter shares a new screening strategy. Learn more about it here https://at.zacks.com/?id=112

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time!Click here for your free subscription to Profit from the Pros.

Get the full Report on CC - FREE

Get the full Report on HAE - FREE

Get the full Report on BCO - FREE

Follow us on Twitter: 

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch">https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: https://www.zacks.com/performance

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Chemours Company (The) (CC): Free Stock Analysis Report
 
Haemonetics Corporation (HAE): Free Stock Analysis Report
 
Brink's Company (The) (BCO): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research